|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Ten factors potentially influencing the progression-free survival were studied: patients' age, gender, smoking history, number of comorbidities, performance status, tumor mutation site, maximum of standardized uptake value (SUV<sub>max</sub>) of primary tumor in FDG PET/CT, serum CEA level, number of metastatic organs and presence of pleural/pericardial effusion.
|
31846863 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.
|
31612350 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Vitamin D effect in xenograft tissue was assessed by monitoring tumor size (<sup>18</sup>F-FDG positron-emission tomography/computerized tomography and macroscopic examination), cell proliferation (immunohistochemistry and quantitative real-time polymerase chain reaction [qRT-PCR]), ECM (Western blot), transforming growth factor (TGF) β3 (qRT-PCR), and apoptosis (Westrn blot and TUNEL).
|
31739978 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study is to evaluate and compare the contrast-enhanced CT and the <sup>18</sup>F-FDG PET/CT methods of imaging in terms of the oesophageal cancer staging and restaging using the eighth edition of the tumor-node-metastasis (TNM) classification.
|
31802058 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes.
|
31720757 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline tumor burden (TMTV) on FDG PET/CT scans and inflammatory status (dNLR) were associated with poor OS and absence of DCB for ICI treatment in advanced NSCLC patients, unlike tumor SUVmax, and may be used together to improve the selection of appropriate candidates.
|
31754795 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a significant difference in the uptake of 68Ga-NOTA-MAL-Cys39-exendin-4 between PC-12 poorly and highly differentiated tumors (p < 0.001), but no significant difference could be observed by 18F-FDG PET.
|
31686522 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
18F-FDG PET/CT metabolic parameters were analyzed as absolute values as well as percentage changes (Δ) between 2 consecutive scans, for primary tumor (T) and for regional lymph nodes (N).
|
31409523 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The pretreatment metabolic <sup>18</sup>F-FDG PET/CT parameters may reflect tumor aggressiveness in patients with salivary gland ACC and may potentially be utilized as a prognostic biomarker.
|
30308429 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we used <sup>18</sup>F-FDG PET/CT imaging to investigate whether artificial nutrition has an impact on tumour glucose metabolism in patients with cancer and cachexia.
|
30209026 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Imaging tumors with tracers that are specifically binding to a tumor-associated antigen can increase diagnostic accuracy, enables monitoring of treatment efficacy, and can be advantageous compared to radiolabeled small molecules used in PET-oncology such as 2-deoxy-2-[<sup>18</sup>F]-fluoro-D-glucose ([<sup>18</sup>F]FDG; glucose metabolism) or [<sup>11</sup>C]choline (membrane synthesis) which was used to image prostate cancer.
|
30445280 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor size and clinical features may be associated with increased FDG uptake in PSPs.
|
31131992 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prognostic Significance of <sup>18</sup>F-FDG PET/CT Metabolic Parameters and Tumor Galectin-1 Expression in Patients With Surgically Resected Lung Adenocarcinoma.
|
31300363 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of FDG-PET for Gross Tumor volume identification is crucial, representing a useful and powerful tool for anal and rectal cancer.
|
30940428 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This retrospective cohort study included 57 patients (36 males, 21 females, mean age 54 years, range 12-90 years) with pathologically confirmed soft tissue (<i>n</i> = 32) and bone (<i>n</i> = 25) tumours who underwent 3T MR imaging including DWI and whole-body 18F-FDG PET/CT before treatment.
|
31322913 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
So, we conclude that <sup>18</sup>F-FDG avidity predicates poor therapeutic effect on tumor size, high risk of disease progression and less favorable prognosis.
|
31273354 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The metabolic pattern on early PET was suggestive of pseudoprogression, which is a rare phenomenon reflecting an activation of inflammatory cells within the tumor microenvironment causing lesions to increase in size and to accumulate FDG until a sufficient immune response is developed.
|
31306191 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup>F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading.
|
31396797 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience.
|
30291373 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup>F-FDG PET/CT scans at baseline and at 12-14 wk after nCRT were qualitatively assessed for the presence of tumor.
|
30877177 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Preoperatively, 13 of the 14 (93%) sets of serial MRI studies and 10 of the 11 (91%) 18F-FDG-PET scans showed rapid growth (≥ 20% increase in volume per year) and avidity (SUVMax ≥ 3.5) of the identified tumor, respectively (median tumor size 48.7 cm3; median growth rate 92% per year; median SUVMax 6.45).
|
31653805 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This retrospective study examined whether the primary tumour 18F-FDG uptake features could predict the high-risk of recurrence in differentiated thyroid cancer (DTC) patients.
|
30273012 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
During median follow-up of 24.4±1.5 months 18F-FDG PET/CT and MRI results and tumor marker levels were compared with findings of histopathological examination or with results of clinical and imaging follow-up.
|
28895416 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor Voxel Dose-Response Matrix and Dose Prescription Function Derived Using <sup>18</sup>F-FDG PET/CT Images for Adaptive Dose Painting by Number.
|
30684661 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aims of our study, performed in oncological patients who underwent pre- and post-treatment [<sup>18</sup>F]FDG PET/CT on different scanners, were (1) to evaluate whether EQ·PET, a proprietary SUV inter-exams harmonization tool, modifies the EORTC tumor response classification and (2) to assess which classification (harmonized and non-harmonized) better predicts clinical outcome.
|
30850971 |
2019 |